3.15.138.214=3.1
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=33972494&retmode=xml&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b49083.15.138.214=3.1
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=pulmonary+metastasectomy&datetype=edat&usehistory=y&retmax=5&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b49083.15.138.214=3.1
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&WebEnv=MCID_67957a41ada43c480f0b9ed6&query_key=1&retmode=xml&retmax=5&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908 Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. | LitMetric

BACKGROUND Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) results in poor survival outcome. This study assessed the clinical outcomes of pulmonary metastasectomy in LT recipients with pulmonary metastasis of HCC in a high-volume transplant center and analyzed factors prognostic of survival following metastasectomy. MATERIAL AND METHODS This study analyzed outcomes in 52 patients who underwent pulmonary resection due to pulmonary metastasis as the first recurrence of HCC after LT from January 2004 to December 2017 in a single center. RESULTS The 52 enrolled patients included 46 men and 6 women, aged 56.0±6.6 years. Their 1-, 3-, and 5-year survival rates after pulmonary resection were 75.0%, 43.5%, and 33.9%, respectively. The 1-, 3-, and 5-year survival rates were 85.3%, 47.1%, and 34.2%, respectively, in patients with further metastases and 55.6%, 38.1%, and 38.1%, respectively, in patients without further metastases (P=0.45). The size and number of pulmonary metastatic nodules were unrelated to survival rates (all P>0.10). A shorter recurrence-free period after LT (hazard ratio [HR]=0.553, P=0.006), elevated alpha-fetoprotein concentration at metastasectomy (HR=2.142, P=0.03), and adjuvant chemotherapy after metastasectomy (HR=3.79, P=0.003) were independent risk factors for survival after metastasectomy. CONCLUSIONS Pulmonary metastasectomy for HCC recurrence in LT recipients showed favorable survival outcomes. Independent risk factors for survival after metastasectomy included recurrence-free survival after LT, alpha-fetoprotein level at metastasectomy, and adjuvant chemotherapy after metastasectomy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122851PMC
http://dx.doi.org/10.12659/AOT.930383DOI Listing

Publication Analysis

Top Keywords

pulmonary metastasectomy
12
survival metastasectomy
12
survival rates
12
metastasectomy
10
survival
9
pulmonary
8
hepatocellular carcinoma
8
pulmonary metastasis
8
pulmonary resection
8
5-year survival
8

Similar Publications

Introduction: Patients with metastatic melanoma to the lung typically have poor outcomes. Although a pulmonary metastasectomy for selected patients has been shown to improve survival, the role of surgical resection following the introduction of immunotherapy for metastatic melanoma is unknown. The objective of this study was to determine predictors of survival for patients with melanoma metastatic to the lung in the era of immunotherapy.

View Article and Find Full Text PDF

Location of Primary Tumor Impacts Survival After Pulmonary Metastasectomy for Colorectal Cancer.

J Gastrointest Surg

January 2025

Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Background: The benefit of pulmonary metastasectomy (PM) in patients with colorectal cancer (CRC) with isolated lung metastases remains unclear and failure to separate colon from rectal cancer may contribute. Utilizing a large national database, we investigate whether PM is associated with survival benefits in patients presenting with CRC with synchronous lung metastases based upon primary tumor location.

Methods: The Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 was queried to identify patients with stage IV CRC with isolated synchronous lung metastases at initial diagnosis.

View Article and Find Full Text PDF

The Scenic Route: Lingular Metastasectomy Through the Right Chest.

Ann Thorac Surg Short Rep

September 2024

Division of Thoracic Surgery, Department of Surgery, Yale-New Haven Hospital, New Haven, Connecticut.

Metastasectomy for isolated pulmonary metastasis can improve disease-free and overall-survival in well-selected patients. When feasible, a minimally invasive wedge resection is the preferred approach. However, a hostile ipsilateral chest can hinder surgical resection.

View Article and Find Full Text PDF

Pneumonectomy for Osteosarcoma Metastases: Two Compelling Cases With Unique Radiology.

Ann Thorac Surg Short Rep

September 2024

Division of Thoracic Surgery, Department of Surgery, Dalhousie University, Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada.

Osteosarcoma, the most common primary bone tumor in young individuals, frequently metastasizes hematogenously to the lungs, necessitating pulmonary metastasectomy as a common surgical procedure. While sublobar and lobar resections are accepted approaches, pneumonectomy is considered a major intervention. In this report, we present 2 intriguing cases of patients who underwent pneumonectomy for pulmonary osteosarcoma metastases, emphasizing the challenges of careful patient selection and surgical planning.

View Article and Find Full Text PDF

Introduction: Children and young adults diagnosed with sarcoma often present with pulmonary metastases requiring wedge resection. It is important to balance the risk of pulmonary recurrence against the desire to limit resection of benign parenchyma. This study aims to determine the impact of resection margins on survival and recurrence among pediatric and young adult sarcoma patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!